サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1412528

遺伝性血管性浮腫治療薬市場：薬剤クラス別、治療タイプ別、投与経路別-2024-2030年の世界予測

Hereditary Angioedema Therapeutics Market by Drug Class (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor, Kallikrein Inhibitor), Treatment Type (On-Demand, Prophylaxis), Route Of Administration - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
遺伝性血管性浮腫治療薬市場：薬剤クラス別、治療タイプ別、投与経路別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

遺伝性血管性浮腫治療薬市場規模は2023年に365億9,000万米ドルと推計され、2024年には382億9,000万米ドルに達し、CAGR 6.04%で2030年には551億9,000万米ドルに達すると予測されます。

遺伝性血管性浮腫治療薬の世界市場

主な市場の統計
基準年[2023］ 365億9,000万米ドル
予測年[2024] 382億9,000万米ドル
予測年 [2030] 551億9,000万米ドル
CAGR（%） 6.04%
遺伝性血管性浮腫治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは遺伝性血管性浮腫治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、遺伝性血管性浮腫治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-遺伝性血管性浮腫治療薬市場の市場規模および予測は？

2-遺伝性血管性浮腫治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-遺伝性血管性浮腫治療薬市場における技術動向と規制の枠組みは？

4-遺伝性血管性浮腫治療薬市場における主要ベンダーの市場シェアは？

5-遺伝性血管性浮腫治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 遺伝性血管浮腫の症例が世界中で増加
      • 病気に対する意識を高めるための取り組みが急増
      • 遺伝性血管浮腫の不適切な治療
    • 抑制要因
      • HAE治療薬の副作用への懸念
    • 機会
      • 遺伝性血管浮腫治療薬の承認の増加
      • 遺伝性血管浮腫の新規治療法の開発に焦点が当てられる可能性
    • 課題
      • HAEの状態に関する認識の欠如
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 遺伝性血管性浮腫治療薬市場薬剤クラス別

  • ブラジキニンB2受容体拮抗薬
  • C1-エステラーゼ阻害剤
  • カリクレイン阻害剤

第7章 遺伝性血管性浮腫治療薬市場治療タイプ別

  • オンデマンド
  • 予防

第8章 遺伝性血管性浮腫治療薬市場：投与経路別

  • 静脈内
  • オーラル
  • 皮下

第9章 南北アメリカの遺伝性血管性浮腫治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の遺伝性血管性浮腫治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの遺伝性血管性浮腫治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Astria Therapeutics, Inc.
    • Attune Pharmaceuticals
    • BioCryst Pharmaceuticals, Inc.
    • BioMarin Pharmaceutical Inc.
    • Centogene N.V.
    • Cipla Inc.
    • CSL Limited
    • Intellia Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Pharming Group N.V.
    • Pharvaris GmbH
    • Takeda Pharmaceutical Company Limited
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY BRADYKININ B2 RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-742BD517F735

[190 Pages Report] The Hereditary Angioedema Therapeutics Market size was estimated at USD 36.59 billion in 2023 and expected to reach USD 38.29 billion in 2024, at a CAGR 6.04% to reach USD 55.19 billion by 2030.

Global Hereditary Angioedema Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 36.59 billion
Estimated Year [2024] USD 38.29 billion
Forecast Year [2030] USD 55.19 billion
CAGR (%) 6.04%
Hereditary Angioedema Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hereditary Angioedema Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hereditary Angioedema Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Angioedema Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., Astria Therapeutics, Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Centogene N.V., Cipla Inc., CSL Limited, Intellia Therapeutics, Inc., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Pharming Group N.V., Pharvaris GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Hereditary Angioedema Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Bradykinin B2 Receptor Antagonist
    • C1-Esterase Inhibitor
    • Kallikrein Inhibitor
  • Treatment Type
    • On-Demand
    • Prophylaxis
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hereditary Angioedema Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hereditary Angioedema Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Hereditary Angioedema Therapeutics Market?

4. What is the market share of the leading vendors in the Hereditary Angioedema Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Hereditary Angioedema Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hereditary Angioedema Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of hereditary angioedema across the globe
      • 5.1.1.2. Surging initiatives to improve the awareness about the disease
      • 5.1.1.3. Inadequate treatment of the hereditary angioedema
    • 5.1.2. Restraints
      • 5.1.2.1. Concern regarding adverse reactions of HAE therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in approvals of hereditary angioedema drugs
      • 5.1.3.2. Potential focus on developing novel therapeutics for hereditary angioedema
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness about HAE conditions
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Bradykinin B2 Receptor Antagonist
  • 6.3. C1-Esterase Inhibitor
  • 6.4. Kallikrein Inhibitor

7. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. On-Demand
  • 7.3. Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous

9. Americas Hereditary Angioedema Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hereditary Angioedema Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hereditary Angioedema Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Adverum Biotechnologies, Inc.
    • 13.1.2. Arrowhead Pharmaceuticals, Inc.
    • 13.1.3. Astria Therapeutics, Inc.
    • 13.1.4. Attune Pharmaceuticals
    • 13.1.5. BioCryst Pharmaceuticals, Inc.
    • 13.1.6. BioMarin Pharmaceutical Inc.
    • 13.1.7. Centogene N.V.
    • 13.1.8. Cipla Inc.
    • 13.1.9. CSL Limited
    • 13.1.10. Intellia Therapeutics, Inc.
    • 13.1.11. Ionis Pharmaceuticals, Inc.
    • 13.1.12. KalVista Pharmaceuticals, Inc.
    • 13.1.13. Pharming Group N.V.
    • 13.1.14. Pharvaris GmbH
    • 13.1.15. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing